Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS‐stimulated macrophages via inactivating MAPK signaling pathway
Immunity, Inflammation and Disease · 2024
DOI: 10.1002/iid3.1077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Hong Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of TCM and Integrated TCM and Western Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal Universi…. Hauptthemen laut MEDLINE: Lipopolysaccharides, Inflammatory Bowel Diseases, MAP Kinase Signaling System, Macrophages. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Considering the antihepatitis effects of Tectorigenin (TEC), and the same adenosine mitogen‐activated protein kinase (MAPK) pathway in both hepatitis and inflammatory bowel disease (IBD) models, exploring the role of TEC in IBD is contributive to develop a new treatment strategy against IBD.
Methods
The IBD mouse model was constructed by feeding with dextran sodium sulfate (DSS) and injection of TEC. Afterward, the mouse body weight, colon length, and disease activity index (DAI) were tested to assess the enteritis level. Mouse intestine lesions were detected by hematoxylin and eosin staining. Murine macrophages underwent lipopolysaccharide (LPS) induction to establish an inflammation model. Cell viability was determined by cell counting kit‐8 assay. Enzyme‐linked immunosorbent assay was performed to measure interleukin 6 (IL‐6) and tumor necrosis factor‐α (TNF‐α) levels. Cyclooxygenase‐2 (COX‐2) and inducible nitric oxide synthase (iNOS) expressions were quantified via quantitative reverse transcription polymerase chain reaction. Levels of MAPK pathway‐related proteins (p‐P38, P38, p‐Jun N‐terminal kinase (JNK), JNK, signal‐regulated kinase (ERK), p‐ERK), COX‐2 and iNOS were quantitated by Western blot.
Results
TEC improved the inflammatory response through ameliorating weight loss, shortening colon, and increasing DAI score in IBD mouse. Expressions of intestinal inflammatory factors (IL‐6, TNF‐α, iNOS and COX‐2) and MAPK pathway‐related proteins (p‐P38, p‐JNK, and p‐ERK) were increased both in DSS‐induced mouse intestinal tissue, but TEC inhibited expressions of inflammatory factors. The same increased trend was identified in LPS‐induced macrophages, but TEC improved macrophage inflammation, as evidenced by downregulation of inflammatory factors.
Conclusion
TEC mitigates IBD and LPS‐induced macrophage inflammation in mice via inhibiting MAPK signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of TCM and Integrated TCM and Western Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
- Department of Liver and Gall Surgical, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
ORCID-Profile: Yi Cai
Zitieren
APA
Huang, H., Tang, S., Zhou, Y., & Cai, Y. (2024). Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS‐stimulated macrophages via inactivating MAPK signaling pathway. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1077
Vancouver
Huang H, Tang S, Zhou Y, Cai Y. Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS‐stimulated macrophages via inactivating MAPK signaling pathway. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.1077
BibTeX
@article{Huang2024,
author = {Huang, Hong and Tang, Sanhui and Zhou, Yanghong and Cai, Yi},
title = {Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS‐stimulated macrophages via inactivating MAPK signaling pathway},
journal = {Immunity, Inflammation and Disease},
year = {2024},
doi = {10.1002/iid3.1077}
}
EUVIMED